PTEN: One gene, Many syndromes

Human Mutation

Volumn 22, Issue 3, 2003, Pages 183-198

  Eng, Charis ^a,b  

^a OHIO STATE UNIVERSITY   (United States)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Akt; Bannayan Riley Ruvalcaba syndrome; Cowden syndrome; Multiple hamartoma syndrome; Phosphatase; Proteus syndrome; PTEN

Indexed keywords

PHOSPHATASE; PROTEIN KINASE B;

APOPTOSIS; BANNAYAN RILEY RUVALCABA SYNDROME; CANCER RISK; CELL COMPARTMENTALIZATION; CELL CYCLE G1 PHASE; CHROMOSOME 10Q; CLINICAL FEATURE; CONGENITAL TUMOR; COWDEN SYNDROME; EXON; GENE; GENE INACTIVATION; GENE MUTATION; GENOTYPE PHENOTYPE CORRELATION; GERM LINE; HUMAN; MITOSIS INHIBITION; MULTIPLE CANCER; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DEGRADATION; PTEN GENE; REVIEW; SOMATIC MUTATION; SYNDROME;

ABNORMALITIES, MULTIPLE; ANIMALS; DISEASE MODELS, ANIMAL; GERM-LINE MUTATION; HAMARTOMA SYNDROME, MULTIPLE; HUMANS; PHOSPHORIC MONOESTER HYDROLASES; PROTEUS SYNDROME; PTEN PHOSPHOHYDROLASE; SYNDROME; TUMOR SUPPRESSOR PROTEINS;

EID: 0042316755     PISSN: 10597794     EISSN: None     Source Type: Journal    
DOI: 10.1002/humu.10257     Document Type: Review

References (139)

1. Ahmed SF, Marsh DJ, Weremowicz S, Morton CC, Williams DM, Eng C. 1999. Balanced translocation of 10q and 13q, including the PTEN gene, in a boy with an HCG-secreting tumor and the Bannayan-Riley-Ruvalcaba syndrome. J Clin Endocrinol Metab 84:4665-4670.
2. Arch EM, Goodman BK, van Wesep RA, Liaw D, Clarke K, Parsons R, McKusick VA, Geraghty MT. 1997. Deletion of PTEN in a patient with Bannayan-Riley-Ruvalcaba syndrome suggests allelism with Cowden disease. Am J Med Genet 71:489-493.
3. Barker E, Martinez A, Wang R, Bevan S, Murday V, Shipley J, Houlston R, Harper J. 2001. PTEN mutations are uncommon in Proteus syndrome. J Med Genet 38:480-481.
4. Biesecker LG, Happle R, Mulliken JB, Weksberg R, Graham JM, Viljoen DL, Cohen MM. 1999. Proteus syndrome: diagnostic criteria, differential diagnosis and patient evaluation. Am J Med Genet 84:389-395.
5. Blum RR, Rahimizadeh A, Kardon N, Lebwohl M, Wei H. 2001. Genital lentigines in a 6-year-old boy with a family history of Cowden's disease: clinical and genetic evidence of the linkage between Bannayan-Riley-Ruvalcaba syndrome and Cowden's disease. J Cutan Med Surg 5:228-230.
6. Bonneau D, Longy M. 2000. Mutations of the human PTEN gene. Hum Mutat 16:109-122.
7. Bose S, Wang SI, Terry MB, Hibshoosh H, Parsons R. 1998. Allelic loss of chromosome 10q23 is associated with tumor progression in breast carcinomas. Oncogene 17:123-127.
8. Bruni P, Boccia A, Baldasarre G, Trapasso F, Santoro M, Chiappetta G, Fusco A, Viglietto G. 2000. PTEN expression is reduced in a subset of sporadic thyroid carcinomas: evidence that PTEN-growth suppressing activity in thyroid cancer cells is mediated by p27kip1. Oncogene 19:3146-3155.
9. Carethers JM, Furnari FB, Zigman AF, Lavine JE, Jones MC, Graham GE, Teebi AS, SuHuang H-J, Ha HT, Chauhan DP, Chang CL, Cavanee WK, Boland CR. 1998. Absence of PTEN/MMAC1 germline mutations in sporadic Bannayan-Riley-Ruvalcaba syndrome. Cancer Res 58:2724-2726.
10. Celebi JT, Tsou HC, Chen FF, Zhang H, Ping XL, Lebwohl MG, Kezis J, Peacocke M. 1999. Phenotypic findings of Cowden syndrome and Bannayan-Riley-Ruvalcaba syndrome in a family associated with a single germline mutation in PTEN. J Med Genet 36:360-364.
11. Chen J, Lindblom P, Lindblom A. 1998. A study of the PTEN/MMAC1 gene in 136 breast cancer families. Hum Genet 102:124-125.
12. Cheney IW, Neuteboom STC, Vaillancourt M-T, Ramachandra M, Bookstein R. 1999. Adenovirus-mediated gene entry of MMAC1/PTEN to glioblastoma inhibits S phase entry by the recruitment of p27Kip1 and cyclin E/CDK2 complexes. Cancer Res 59:2318-2323.
13. Dahia PLM, Marsh DJ, Zheng Z, Zedenius J, Komminoth P, Frisk T, Wallin G, Parsons R, Longy M, Larsson C, Eng C. 1997. Somatic deletions and mutations in the Cowden disease gene, PTEN, in sporadic thyroid tumors. Cancer Res 57:4710-4713.
14. Dahia PLM, Gimm P, Chi H, Marsh DJ, Reynolds PR, Eng C. 2000. Absence of germline mutations in MINPP1, a phosphatase-encoding gene centromeric of PTEN, in patients with Cowden and Bannayan-Riley-Ruvalcaba syndrome without germline PTEN mutations. J Med Genet 37:715-717.
15. Dasouki MJ, Ishmael H, Eng C. 2001. Macrocephaly, macrosomia and autistic behavior due to a de novo PTEN germline mutation. (Abstract 564) Am J Hum Genet 69S:280.
16. Davies MA, Lu Y, Sano T, Fang X, Tang P, LaPuschin R, Koul D, Bookstein R, Stokoe D, Yung WKA, Mills GB, Steck PA. 1998. Adenoviral transgene expression of MMAC/PTEN in human glioma cells inhibits Akt activation and induces anoikis. Cancer Res 58:5285-5290.
17. Davies MA, Kim SJ, Parikh NU, Dong Z, Bucana CD, Gallick GE. 2002. Adenoviral-mediated expression of MMAC/PTEN inhibits proliferation and metastasis of human prostate cancer cells. Clin Cancer Res 8:1904-1914.
18. DeVivo I, Gertig D, Nagase S, Hankinson SE, OBrien R, Speizer FE, Parsons R, Hunter DJ. 2000. Novel germline mutations in the PTEN tumour suppressor gene found in women with multiple cancers. J Med Genet 37:336-341.
19. Devriendt K, DeCock P, Fryns JP. 1995. Hydrocephalus with features of VATER. J Genet Counsel 6:69.
20. Di Cristofano A, Pesce B, Cordon-Cardo C, Pandolfi PP. 1998. Pten is essential for embryonic development and tumour suppression. Nat Genet 19:348-355.
21. Di Cristofano A, Kotsi P, Peng YF, Cordon-Cardo C, Elkon KB, Pandolfi PP. 1999. Impaired Fas response and autoimmunity in Pten +/- mice. Science 285:2122-2125.
22. Dürr E-M, Rollbrocker B, Hayashi Y, Peters N, Meyer-Puttlitz B, Louis DN, Schramm J, Wiestler OD, Parsons R, Eng C, von Deimling A. 1998. PTEN mutations in gliomas and glioneuronal tumours. Oncogene 16:2259-2264.
23. Eng C, Clayton D, Schuffenecker I, Lenoir G, Cote G, Gagel RF, Ploos van Amstel HK, Lips CJM, Nishisho I, Takai S-I, Marsh DJ, Robinson BG, Frank-Raue K, Raue F, Xue F, Noll WW, Romei C, Pacini F, Fink M, Niederle B, Zedenius J, Nordenskjöld M, Komminoth P, Hendy GN, Gharib H, Thibodeau SN, Lacroix A, Frilling A, Ponder BAJ, Mulligan LM. 1996a. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2: international RET mutation consortium analysis. JAMA 276:1575-1579.
24. Eng C, Mulligan LM, Healey CS, Houghton C, Frilling A, Raue F, Thomas GA, Ponder BAJ. 1996b. Heterogeneous mutation of the RET proto-oncogene in subpopulations of medullary thyroid carcinoma. Cancer Res 56:2167-2170.
25. Eng C, Ji H. 1998. Molecular classification of the inherited hamartoma polyposis syndromes: clearing the muddied waters. Am J Hum Genet 62:1020-1022.
26. Eng C, Parsons R. 1998. In: Vogelstein B, Kinzler KW, editors. Cowden syndrome. The genetic basis of human cancer. New York: McGraw-Hill. p 519-526.
27. Eng C. 1999. RET proto-oncogene in the development of human cancer. J Clin Oncol 17:380-393.
28. Eng C. 2000. Will the real Cowden syndrome please stand up: revised diagnostic criteria. J Med Genet 37:828-830.
29. Eng C. 2001. News and views: to be or not to BMP. Nat Genet 28:105-107.
30. Eng C, Brody LC, Wagner TMU, Devilee P, Vijg J, Szabo C, Tavtigian S, Nathanson KL, Ostrander E, Frank TS, BIC. 2001. Interpretation of molecular epidemiologic research: blinded comparison of methods for detecting germline BRCA1 mutations. J Med Genet 38:824-833.
31. Fackenthal J, Marsh DJ, Richardson AL, Cummings SC, Eng C, Robinson BG, Olopade OI. 2001. Male breast cancer in Cowden syndrome patients with germline PTEN mutations. J Med Genet 38:159-164.
32. Feilotter HE, Coulon V, McVeigh JL, Boag AH, Dorion-Bonnet F, Duboué B, Latham WCW, Eng C, Mulligan LM, Longy M. 1999. Analysis of the 10q23 chromosomal region and the PTEN gene in human sporadic breast carcinoma. Br J Cancer 79:718-723.
33. Fernandez M, Eng C. 2002. The biology behind the expanding role of PTEN in neoplasia: a molecule for all seasons? Clin Cancer Res 8:1695-1698.
34. FitzGerald MG, Marsh DJ, Wahrer D, Caron S, Bell S, Shannon KEM, Ishioka C, Isselbacher KJ, Garber JE, Eng C, Haber DA. 1998. Germline mutations in PTEN are an infrequent cause of genetic predisposition to breast cancer. Oncogene 17:727-731.
35. Furnari FB, Lin H, Huang H-JS, Cavanee WK. 1997. Growth suppression of glioma cells by PTEN requires a functional catalytic domain. Proc Natl Acad Sci USA 94:12479-12484.
36. Furnari FB, SuHuang H-J, Cavanee WK. 1998. The phosphoinositol phosphatase activity of PTEN mediates a serum-sensitive G1 growth arrest in glioma cells. Cancer Res 58:5002-5008.
37. Georgescu M-M, Kirsch KH, Akagi T, Shishido T, Hanafusa H. 1999. The tumor-suppressor activity of PTEN is regulated by its carboxy-terminal region. Proc Natl Acad Sci USA 96:10182-10187.
38. Gimm O, Perren A, Weng LP, Marsh DJ, Yeh JJ, Ziebold U, Gil E, Hinze R, Delbridge L, Lees JA, Robinson BG, Komminoth P, Dralle H, Eng C. 2000. Differential nuclear and cytoplasmic expression of PTEN in normal thyroid tissue, and benign and malignant epithelial thyroid tumors. Am J Pathol 156:1693-1700.
39. Ginn-Pease ME, Eng C. 2003. Increased nuclear phosphatase and tensin homologue deleted on chromosome 10 is associated with G0G1 in MCF-7 cells. Cancer Res 63:282-286.
40. Gorlin RJ, Cohen MM, Condon LM, Burke BA. 1992. Bannayan-Riley-Ruvalcaba syndrome. Am J Med Genet 44:307-314.
41. Gu J, Tamura M, Yamada KM. 1998. Tumor suppressor PTEN inhibits integrin- and growth factor-mediated mitogen-activated protein (MAP) kinase signaling pathway. J Cell Biol 143:1375-1383.
42. Haas-Kogan D, Shalev N, Wong M, Mills G, Yount G, Stokoe D. 1998. Protein kinase B (PKB/Akt) activity is elevated in glioblastoma cells due to mutation of the tumor suppressor PTEN/MMAC1. Curr Biol 8:1195-1198.
43. Halachmi N, Halachmi S, Evron E, Parsons R, Sidransky D. 1998. Somatic mutations of the PTEN tumor suppressor gene in sporadic follicular thyroid tumors. Gene Chrom Cancer 23:239-243.
44. Han S-Y, Kato H, Suzuki T, Shibata H, Ishii S, Shiba K-i, Matsuno S, Kanamaru R, Ishioka C. 2000. Functional evaluation of PTEN missense mutations using in vitro phosphoinositide phosphatase assay. Cancer Res 60:3147-3151.
45. Hanssen AMN, Fryns JP. 1995. Cowden syndrome. J Med Genet 32:117-119.
46. Harada N, Sugimura T, Yoshimura R, Motomura S, Shirahama S, Naramoto J, Chijiwa Y, Nakamura K, Ito K, Nawata H. 2003. Novel germline mutation of the PTEN gene in a Japanese family with Cowden disease. J Gastroenterol 38:87-91.
47. Hemminki A, Tomlinson I, Markie D, Järvinen H, Sistonen P, Björkqvist A-M, Knuutila S, Salovaara R, Bodmer W, Shibata D, de la Chapelle A, Aaltonen LA. 1997. Localisation of a susceptibility locus for Peutz-Jeghers syndrome to 19p using comparative genomic hybridization and targeted linkage analysis. Nat Genet 15:87-90.
48. Hemminki A, Markie D, Tomlinson I, Avizienyte E, Roth S, Loukola A, Bignell G, Aminoff WM, Högland P, Järvinen H, Kristo P, Pelin K, Ridanpää M, Salovaara R, Toro T, Bodmer W, Olschwang S, Olsen AS, Stratton MR, de la Chapelle A, Aaltonen LA. 1998. A serine/threonine kinase gene defective in Peutz-Jeghers syndrome. Nature 391:184-187.
49. Howe JR, Ringold JC, Summers RW, Mitros FA, Nishimura DY, Stone EM. 1998a. A gene for familial juvenile polyposis maps to chromosome 18q21.1. Am J Hum Genet 62:1129-1136.
50. Howe JR, Roth S, Ringold JC, Summers RW, Jarvinen HJ, Sistonen P, Tomlinson IPM, Houlston RS, Bevan S, Mitros FA, Stone EM, Aaltonen LA. 1998b. Mutations in the SMAD4/DPC4 gene in juvenile polyposis. Science 280:1086-1088.
51. Howe JR, Blair JA, Sayed MG, Anderson ME, Mitros FA, Petersen GM, Velculescu VE, Traverso G, Vogelstein B. 2001. Germline mutations of BMPR1A in juvenile polyposis. Nat Genet 28:184-187.
52. Huang SC, Chen CR, Lavine JE, Taylor SF, Newbury RO, Pham TT, Ricciardello L, Carethers JM. 2000. Genetic heterogeneity in familial juvenile polyposis. Cancer Res 60:6882-6885.
53. Hyun T, Yam A, Pece S, Xie X, Zhang J, Mikei T, Gutkind JS, Li W. 2000. Loss of PTEN expression leading to high Akt activation in human multiple myelomas. Blood 96:3560-3568.
54. Jenne DE, Reimann H, Nezu J-i, Friedel W, Loff S, Jeschke R, Müller O, Back W, Zimmer M. 1998. Peutz-Jeghers syndrome is caused by mutations in a novel serine threonine kinase. Nat Genet 18:38-44.
55. Kong D, Suzuki A, Zou T-T, Sakurada A, Kemp LW, Wakatsuki S, Yokohama T, Yamakawa H, Furukawa T, Sato M, Ohuchi N, Sato S, Yin J, Want S, Abraham JM, Souza RF, Smolinksi KN, Meltzer SJ, Horii A. 1997. PTEN1 is frequently mutated in primary endometrial carcinomas. Nat Genet 17:143-144.
56. Kubo Y, Urano Y, Hida Y, Ikeuchi Y, Nomoto M, Kunitomo K, Arase S. 2000. A novel PTEN mutation in a Japanese patient with Cowden disease. Br J Dermatol 142:1100-1105.
57. Kurose K, Araki T, Matsunaka T, Takada Y, Emi M. 1999. Variant manifestation of Cowden disease in Japan: hamartomatous polyposis of the digestive tract with mutation of the PTEN gene. Am J Hum Genet 64:308-310.
58. Kurose K, Zhou XP, Araki T, Eng C. 2000. Biallelic inactivating mutations and an occult germline mutation of PTEN in primary cervical carcinomas. Gene Chrom Cancer 29:166-172.
59. Kurose K, Hoshaw-Woodard S, Adeyinka A, Lemeshow S, Watson PH, Eng C. 2001a. Genetic model of multi-step breast carcinogenesis involving the epithelium and stroma: clues to tumour-microenvironment interactions. Hum Mol Genet 10:1907-1913.
60. Kurose K, Zhou X-P, Araki T, Cannistra SA, Maher ER, Eng C. 2001b. Frequent loss of PTEN expression is linked to elevated phosphorylated Akt levels, but not associated with p27 and cyclin D1 expression, in primary epithelial ovarian carcinomas. Am J Pathol 158:2097-2106.
61. Kurose K, Gilley K, Matsumoto S, Watson PH, Zhou XP, Eng C. 2002. Frequent somatic mutations in PTEN and TP53 are mutually exclusive in the stroma of breast carcinomas. Nat Genet 32:355-357.
62. Lee J, Yang H, Georgescu M-M, Di Cristafano A, Maehama T, Shi Y, Dixon JE, Pandolfi P, Pavletich NP. 1999. Crystal structure of the PTEN tumor suppressor: implications for its phosphoinositide phosphatase activity and membrane association. Cell 99:323-334.
63. Li D-M, Sun H. 1997. TEP1, encoded by a candidate tumor suppressor locus, is a novel protein tyrosine phosphatase regulated by transforming growth factor B. Cancer Res 57:2124-2129.
64. Li DM, Sun H. 1998. PTEN/MMAC1/TEP1 suppresses the tumorigenicity and induces G1 cell cycle arrest in human glioblastoma cells. Proc Natl Acad Sci USA 95:15406-15411.
65. Li G, Robinson GW, Lesche R, Martinez-Diaz H, Jiang Z, Rozenburt N, Wagner KU, Wu DC, Lane TF, Liu X, Hennighausen L, Wu H. 2002. Conditional loss of Pten leads to precocious development and neoplasia in the mammary gland. Development 129:4159-4170.
66. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang S, Puc J, Miliaresis C, Rodgers L, McCombie R, Bigner SH, Giovanella BC, Ittman M, Tycko B, Hibshoosh H, Wigler MH, Parsons R. 1997. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast and prostate cancer. Science 275:1943-1947.
67. Li J, Simpson L, Takahashi M, Miliaresis C, Myers MP, Tonks N, Parsons R. 1998. The PTEN/MMAC1 tumor suppressor induces cell death that is rescued by the AKT/protein kinase B oncogene. Cancer Res 58:5667-5672.
68. Liaw D, Marsh DJ, Li J, Dahia PLM, Wang SI, Zheng Z, Bose S, Call KM, Tsou HC, Peacocke M, Eng C, Parsons R. 1997. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet 16:64-67.
69. Longy M, Lacombe D. 1996. Cowden disease. Report of a family and review. Ann Génet 39:35-42.
70. Longy M, Coulon V, Duboué DA, Larrègue M, Eng C, Amati P, Kraimps J-L, Bottani A, Lacombe D, Bonneau D. 1998. Mutations of PTEN in patients with Bannayan-Riley-Ruvalcaba phenotype. J Med Genet 35:886-889.
71. Lynch ED, Ostermeyer EA, Lee MK, Arena JF, Ji H, Dann J, Swisshelm K, Suchard D, MacLeod PM, Kvinnsland S, Gjertsen BT, Heimdal K, Lubs H, Moller P, King M-C. 1997. Inherited mutations in PTEN that are associated with breast cancer, Cowden syndrome and juvenile polyposis. Am J Hum Genet 61:1254-1260.
72. Maehama T, Dixon JE. 1998. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger phosphoinositol 3,4,5-triphosphate. J Biol Chem 273:13375-13378.
73. Mallory SB. 1995. Cowden syndrome (multiple hamartoma syndrome). Dermatol Clin 13:27-31.
74. Marsh DJ, Dahia PLM, Zheng Z, Liaw D, Parsons R, Gorlin RJ, Eng C. 1997a. Germline mutations in PTEN are present in Bannayan-Zonana syndrome. Nat Genet 16:333-334.
75. Marsh DJ, Roth S, Lunetta K, Hemminki A, Dahia PLM, Sistonen P, Zheng Z, Caron S, van Orsouw NJ, Bodmer WF, Cottrell S, Dunlop MG, Eccles D, Hodgson SV, Järvinen H, Kellokumpu I, Markie D, Neale K, Phillips R, Rozen P, Syngal S, Vijg J, Tomlinson IPM, Aaltonen LA, Eng C. 1997b. Exclusion of PTEN and 10q22-24 as the susceptibility locus for juvenile polyposis syndrome (JPS). Cancer Res 57:5017-5021.
76. Marsh DJ, Caron S, Dahia PLM, Kum JB, Frayling IM, Tomlinson IPM, Hughes KS, Hodgson SV, Murday VA, Houlston R, Eng C. 1998a. Germline PTEN mutations in Cowden syndrome-like families. J Med Genet 35:881-885.
77. Marsh DJ, Coulon V, Lunetta KL, Rocca-Serra P, Dahia PLM, Zheng Z, Liaw D, Caron S, Duboué B, Lin AY, Richardson A-L, Bonnetblanc J-M, Bressieux J-M, Cabarrot-Moreau A, Chompret A, Demange L, Eeles RA, Yahanda AM, Fearon ER, Fricker J-P, Gorlin RJ, Hodgson SV, Huson S, Lacombe D, LePrat F, Odent S, Toulouse C, Olopade OI, Sobol H, Tishler S, Woods CG, Robinson BG, Weber HC, Parsons R, Peacocke M, Longy M, Eng C. 1998b. Mutation spectrum and genotype-phenotype analyses in Cowden disease and Bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN mutation. Hum Mol Genet 7:507-515.
78. Marsh DJ, Kum JB, Lunetta KL, Bennett MJ, Gorlin RJ, Ahmed SF, Bodurtha J, Crowe C, Curtis MA, Dazouki M, Dunn T, Feit H, Geraghty MT, Graham JM, Hodgson SV, Hunter A, Korf BR, Manchester D, Miesfeldt S, Murday VA, Nathanson KA, Parisi M, Pober B, Romano C, Tolmie JL, Trembath R, Winter RM, Zackai EH, Zori RT, Weng LP, Dahia PLM, Eng C. 1999. PTEN mutation spectrum and genotype -phenotype correlations in Bannayan-Riley-Ruvalcaba syndrome suggest a single entity with Cowden syndrome. Hum Mol Genet 8:1461-1472.
79. Mulligan LM, Gardner E, Smith BA, Mathew CGP, Ponder BAJ. 1993. Genetic events in tumor initiation and progression in multiple endocrine neoplasia. Genes Chrom Cancer 6:166-177.
80. Mutter GL, Lin M-C, Fitzgerald JT, Kum JB, Baak JPA, Lees JA, Weng L-P, Eng C. 2000a. Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J Natl Cancer Inst 92:924-931.
81. Mutter GL, Lin M-C, FitzGerald JT, Kum JB, Eng C. 2000b. Changes in endometrial PTEN expression throughout the human menstrual cycle. J Clin Endocrinol Metab 85:2334-2338.
82. Mutter GL, Ince T, Baak JPA, Kurst GA, Zhou XP, Eng C. 2001. Molecular identification of latent precancers in histologically normal endometrium. Cancer Res 61:4311-4314.
83. Myers MP, Stolarov J, Eng C, Li J, Wang SI, Wigler MH, Parsons R, Tonks NK. 1997. PTEN, the tumor suppressor from human chromosome 10q23, is a dual specificity phosphatase. Proc Natl Acad Sci USA 94:9052-9057.
84. Myers MP, Tonks NK. 1997. PTEN: Sometimes taking it off can be better than putting it on. Am J Hum Genet 61:1234-1238.
85. Myers MP, Pass I, Batty IH, van der Kaay J, Storalov JP, Hemmings BA, Wigler MH, Downes CP, Tonks NK. 1998. The lipid phosphatase activity of PTEN is critical for its tumor suppressor function. Proc Natl Acad Sci USA 95:13513-13518.
86. NCCN. 1999. NCCN practice guidelines: genetics/familial high risk cancer. Oncology 13(11A):161-186.
87. Nelen MR, Padberg GW, Peeters EAJ, Lin AY, van den Helm B, Frants RR, Coulon V, Goldstein AM, van Reen MMM, Easton DF, Eeles RA, Hodgson S, Mulvihill JJ, Murday VA, Tucker MA, Mariman ECM, Starink TM, Ponder BAJ, Ropers HH, Kremer H, Longy M, Eng C. 1996. Localization of the gene for Cowden disease to 10q22-23. Nat Genet 13:114-116.
88. Nelen MR, van Staveren CG, Peeters EAJ, Ben Hassel M, Gorlin RJ, Hamm H, Lindboe CF, Fryns J-P, Sijmons RH, Woods DG, Mariman ECM, Padberg GW, Kremer H. 1997. Germline mutations in the PTEN/MMAC1 gene in patients with Cowden disease. Hum Mol Genet 6:1383-1387.
89. Nelen MR, Kremer H, Konings IBM, Schoute F, van Essen AJ, Koch R, Woods CG, Fryns J-P, Hamel B, Hoefsloot LH, Peeters EAJ, Padberg GW. 1999. Novel PTEN mutations in patients with Cowden disease: absence of clear genotype-phenotype correlations. Eur J Hum Genet 7:267-273.
90. Neshat MS, Mellinghoff IK, Tran C, Stiles B, Thomas G, Petersen R, Frost P, Gibbons JJ, Wu H, Sawyers CL. 2001. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci USA 98:10314-10319.
91. Olschwang S, Serova-Sinilnikova OM, Lenoir GM, Thomas G. 1998. PTEN germline mutations in juvenile polyposis coli. Nat Genet 18:12-14.
92. Perren A, Weng LP, Boag AH, Ziebold U, Thakore K, Dahia PLM, Komminoth P, Less JA, Mulligan LM, Mutter GL, Eng C. 1999. Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast. Am J Pathol 155:1253-1260.
93. Perren A, Komminoth P, Saremaslani P, Matter C, Feurer S, Lees JA, Heitz PU, Eng C. 2000. Mutation and expression analyses reveal differential subcellular compartmentalization of PTEN in endocrine pancreatic tumors compared to normal islet cells. Am J Pathol 157:1097-1103.
94. Podsypanina K, Ellenson LH, Nemes A, Gu J, Tamura M, Yamada KM, Cordon-Cardo C, Catoretti G, Fisher PE, Parsons R. 1999. Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. Proc Natl Acad Sci USA 96:1563-1568.
95. Reardon W, Zhou XP, Eng C. 2001. A novel germline mutation of the PTEN gene in a patient with macrocephaly, ventricular dilatation and features of VATER association. J Med Genet 38:820-823.
96. Rhei E, Kang L, Bogomoliniy F, Federici MG, Borgen PI, Boyd J. 1997. Mutation analysis of the putative tumor suppressor gene PTEN/MMAC1 in primary breast carcinomas. Cancer Res 57:3657-3659.
97. Risinger JI, Barrett JC, Watson P, Lynch HT, Boyd J. 1996. Molecular genetic evidence of the occurrence of breast cancer as an integral tumor in patients with the hereditary nonpolyposis colorectal carcinoma syndrome. Cancer 77:1836-1843.
98. Risinger JI, Hayes AK, Berchuck A, Barrett JC. 1997. PTEN/MMAC1 mutations in endometrial cancers. Cancer Res 57:4736-4738.
99. Rizo J, Sudhof TC. 1998. C2 domains, structure and function of a universal C2+-binding domain. J Biol Chem 273:15879-15882.
100. Sawada T, Hamano N, Satoh H, Okada T, Takeda Y, Mabuchi H. 2000. Mutation analysis of the PTEN gene in Japanese patients with Cowden disease. Jpn J Cancer Res 91:700-705.
101. Schrager CA, Schneider D, Gruener AC, Tsou HC, Peacocke M. 1997. Clinical and pathological features of breast disease in Cowden's syndrome: an underrecognised syndrome with an increased risk of breast cancer. Hum Pathol 29:47-53.
102. Shugart YY, Cour C, Renard H, Lenoir G, Goldgar D, Teare D, Easton D, Rahman N, Gusterton R, Seal S, Barfoot R, Stratton M, Mangion J, Peelen T, van den Ouweland A, Meijers H, Devilee P, Eccles D, Lynch H, Weber B, Stoppa-Lyonnet D, Bignon Y-J, Chang-Claude J. 1999. Linkage analysis of 56 multiplex families excludes the Cowden disease gene PTEN as a major contributor to familial breast cancer. J Med Genet 36:720-721.
103. Simpson L, Li J, Liaw D, Hennessey I, Oliner J, Christians F, Parsons R. 2001. PTEN expression causes a feedback upregulation of IRS-2 signaling. Mol Cell Biol 21:3947-3958.
104. Singh B, Ittman MM, Krolewski JJ. 1998. Sporadic breast cancers exhibit loss of heterozygosity on chromosome segment 10q23 close to the Cowden disease locus. Genes Chrom Cancer 21:166-171.
105. Smith JM, Kirk EPE, Theodosopoulos G, Marshall G, Walker J, Rogers M, Field M, Brereton JJ, Marsh DJ. 2002. Germline mutation of the tumour suppressor PTEN in Proteus syndrome. J Med Genet 39:937-940.
106. Stambolic V, Suzuki A, de la Pompa JL, Brothers GM, Mirtsos C, Sasaki T, Rulland J, Penninger JM, Siderovski DP, Mak TW. 1998. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 95:1-20.
107. Starink TM, van der Veen JPW, Arwert F, de Waal LP, de Lange GG, Gille JJP, Eriksson AW. 1986. The Cowden syndrome: a clinical and genetic study in 21 patients. Clin Genet 29:222-233.
108. Sun H, Lesche R, Li DM, Lilientol J, Zhang H, Gao J, Garrilova N, Mueller B, Liu X, Wu H. 1999. PTEN modulates cell cycle progression and cell survival by regulating phosphotidylinositol-3,4,5-triphosphate and Akt/protein kinase B signaling pathway. Proc Natl Acad Sci USA 96:6199-6204.
109. Suzuki A, de la Pompa JL, Stambolic V, Elia AJ, Sasaki T, del Barco Barrantes I, Ho A, Wakeham A, Itie A, Khoo W, Fukumoto M, Mak TW. 1998. High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice. Curr Biol 8:1169-1178.
110. Suzuki A, Itami S, Oshishi M, Hamada K, Inoue T, Komazawa N, Senoo H, Sasaki T, Takeda J, Manabe M, Mak TW, Nakano T. 2003. Keratinocyte-specific Pten deficiency results in epidermal hyperplasia, accelerated hair follicle morphogenesis and tumor formation. Cancer Res 63:674-681.
111. Tamura M, Gu J, Matsumoto K, Aota S-I, Parsons R, Yamada KM. 1998. Inhibition of cell migration, spreading and focal adhesions by tumor suppressor PTEN. Science 280:1614-1617.
112. Tamura M, Gu J, Danen EHJ, Takino T, Miyamoto S, Yamada KM. 1999. PTEN interactions with focal adhesion kinase and suppression of the extracellular matrix-dependent phosphotidyinositol 3-kinase/Akt cell survival pathway. J Biol Chem 274:20693-20703.
113. Tashiro H, Blazes MS, Wu R, Cho KR, Bose S, Wang SI, Li J, Parsons R, Ellenson LH. 1997. Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. Cancer Res 57:3935-3940.
114. Teng DH-F, Hu R, Lin H, David T, Iliev D, Frye C, Swedlund B, Hansen KL, Vinson VL, Grumpper KL, Ellis L, El-Naggar A, Frazier M, Jasser S, Langford LA, Lee J, Mills GB, Pershouse MA, Pollack RE, Tornos C, Troncoso P, Yung WKA, Fujii G, Berson A, Bookstein R, Bolen JB, Tavtigian SV, Steck PA. 1997. MMAC1/PTEN mutations in primary tumor specimens and tumor cell lines. Cancer Res 57:5221-5225.
115. Trojan J, Plotz G, Brieger A, Raedle J, Meltzer SJ, Wolter M, Zeuzem S. 2001. Activation of a cryptic splice site of PTEN and loss of heterozygosity in benign skin lesions in Cowden disease. J Invest Dermatol 117:1650-1653.
116. Tsou HC, Teng D, Ping XL, Broncolini V, Davis T, Hu R, Xie X-X, Gruener AC, Schrager CA, Christiano AM, Eng C, Steck P, Ott J, Tavtigian SV, Peacocke M. 1997. Role of MMAC1 mutations in early onset breast cancer: causative in association with Cowden's syndrome and excluded in BRCA1-negative cases. Am J Hum Genet 61:1036-1043.
117. Tsuchiya KD, Wiesner G, Cassidy SB, Limwongse C, Boyle JT, Schwartz S. 1998. Deletion 10q23.2-10q23.33 in a patient with gastrointestinal juvenile polyposis and other features of a Cowden-like syndrome. Gene Chrom Cancer 21:113-118.
118. Vazquez F, Ramaswamy D, Nakamura N, Sellers WR. 2000. Phosphorylation of the PTEN tail regulates protein stability and function. Mol Cell Biol 20:5010-5018.
119. Waite KA, Eng C. 2002. Protean PTEN: form and function. Am J Hum Genet 70:829-844.
120. Waite KA, Eng C. 2003. BMP2 exposure results in decreased PTEN protein degradation leading to increased PTEN levels. Hum Mol Genet 12:679-684.
121. Wang SI, Puc J, Li J, Bruce JN, Cairns P, Sidransky D, Parsons R. 1997. Somatic mutations of PTEN in glioblastoma multiforme. Cancer Res 57:4183-4186.
122. Wanner M, Celebi JT, Peacocke M. 2001. Identification of a PTEN mutation in a family with Cowden syndrome and Bannayan-Zonana syndrome. J Am Acad Dermatol 44:183-187.
123. Weng L-P, Smith WM, Dahia PLM, Ziebold U, Gil E, Lees JA, Eng C. 1999. PTEN suppresses breast cancer cell growth by phosphatase function-dependent G1 arrest followed by apoptosis. Cancer Res 59:5808-5814.
124. Weng LP, Brown JL, Eng C. 2001a. PTEN coordinates G1 arrest by down regulating cyclin D1 via its protein phosphatase activity and up regulating p27 via its lipid phosphatase activity. Hum Mol Genet 10:599-604.
125. Weng LP, Brown JL, Eng C. 2001b. PTEN induces apoptosis and cell cycle arrest through phosphoinositol-3-kinase/Akt-dependent and independent pathways. Hum Mol Genet 10:237-242.
126. Weng LP, Gimm O, Kum JB, Smith WM, Zhou XP, Wynford-Thomas D, Leone G, Eng C. 2001c. Transient ectopic expression of PTEN in thyroid cancer cell lines induces cell cycle arrest and cell type-dependent cell death. Hum Mol Genet 10:251-258.
127. Weng LP, Smith WM, Brown JL, Eng C. 2001d. PTEN inhibits insulin-stimulated MEK/MAPK activation and cell growth by blocking IRS-1 phosphorylation and IRS-1/Grb-2/Sos complex formation in a breast cancer model. Hum Mol Genet 10:605-616.
128. Weng LP, Brown JL, Baker KM, Ostrowski MC, Eng C. 2002. PTEN blocks insulin-mediated Ets-2 phosphorylation through MAP kinase, independent of the phosphoinositide-3-kinase pathway. Hum Mol Genet 11:1687-1696.
129. Whiteman DC, Zhou XP, Cummings MC, Pavey S, Hayward NK, Eng C. 2002. PTEN expression and clinico-pathologic features in a population-based series of primary cutaneous melanoma. Int J Cancer 99:63-67.
130. Zhou XP, Gimm O, Hampel H, Niemann T, Walker MJ, Eng C. 2000a. Epigenetic PTEN silencing in malignant melanomas without PTEN mutation. Am J Pathol 157:1123-1128.
131. Zhou XP, Li YJ, Hoang-Xuan K, Laurent-Puig P, Moktari K, Longy M, Sanson M, Delattre JY, Thomas G, Hamelin R. 2000b. Mutational analysis of the PTEN gene in gliomas: molecular and pathological correlations. Int J Cancer 84:150-154.
132. Zhou XP, Marsh DJ, Hampel H, Mulliken JB, Gimm O, Eng C. 2000c. Germline and germline mosaic mutations associated with a Proteus-like syndrome of hemihypertrophy, lower limb asymmetry, arterio-venous malformations and lipomatosis. Hum Mol Genet 9:765-768.
133. Zhou XP, Hampel H, Thiele H, Gorlin RJ, Hennekam R, Parisi M, Winter RM, Eng C. 2001a. Association of germ-line mutation in the PTEN tumour suppressor gene and a subset of Proteus sand Proteus-like syndromes. Lancet 358:210-211.
134. Zhou XP, Woodford-Richens K, Lehtonen R, Kurose K, Aldred M, Hampel H, Launonen V, Virta S, Pilarski R, Salovaara R, Bodmer WF, Conrad BA, Dunlop M, Hodgson SV, Iwama T, Järvinen H, Kellokumpu I, Kim JC, Leggett B, Markie D, Mecklin J-P, Neale K, Phillips R, Piris J, Rozen P, Houlston R, Aaltonen LA, Tomlinson IPM, Eng C. 2001b. Germline mutations in BMPR1A/ALK3 cause a subset of juvenile polyposis syndrome and of Cowden and Bannayan-Riley-Ruvalcaba syndromes. Am J Hum Genet 69:704-711.
135. Zhou XP, Kuismanen S, Nyström-Lahti M, Peltomaki P, Eng C. 2002a. Distinct PTEN mutational spectra in endometrial carcinomas from hereditary non-polyposis colorectal cancer cases compared to sporadic microsatellite unstable tumors. Hum Mol Genet 11:445-450.
136. Zhou XP, Loukola A, Salovaara R, Nystrom-Lahti M, Peltomäki P, de la Chapelle A, Aaltonen LA, Eng C. 2002b. PTEN mutational spectra, expression levels and subcellular localization in microsatellite stable and unstable colorectal cancers. Am J Pathol 161:439-447.
137. Zhou XP, Waite KA, Pilarski R, Hampel H, Fernandez MJ, Bos C, Dasouki M, Feldman GL, Matloff E, Ivanovich J, Greenberg LA, Patterson A, Pierpont ME, Russo D, Nassif NT, Eng C. 2003. Germline PTEN promoter mutations and deletions in Cowden/Bannayan-Riley-Ruvalcaba syndrome result in aberrant PTEN protein and dysregulation of the phosphoinositol-3-kinase/Akt pathway. Am J Hum Genet in press.
138. Zhu X, Kwon CH, Schlosshauer PW, Ellenson LH, Baker SJ. 2001. PTEN induces G(1) cell cycle arrest and decreases cyclin D3 levels in endometrial carcinoma cells. Cancer Res 61:4569-4575.
139. Zori RT, Marsh DJ, Graham GE, Marliss EB, Eng C. 1998. Germline PTEN mutation in a family with Cowden syndrome and Bannayan-Riley-Ruvalcaba syndrome. Am J Med Genet 80:399-402.